Biosensors and biomarkers for determining gestational diabetes mellitus and jaundice in children

Abstract

Gestational diabetes and jaundice are the correlated diseases predominantly found in mother and newborn child. Jaundice is a neonatal complication with an increased risk when mother has gestational diabetes. Mothers with diabetes at an early stage of gestational age are at higher risk for hyperbilirubinemia (jaundice) and hypoglycemia. So, it is mandatory to monitor the condition of diabetes and jaundice during the pregnancy period for a healthy child and safest delivery. On the other hand, nanotechnology has displayed a rapid advancement that can be implemented to overcome these issues. The development of highperformance diagnosis using appropriate biomarkers provides their efficacy in the detection gestational diabetes and jaundice. This review covers the aspects from a fast-developing field to generate nanosensors in the nanosized dimensions for the applications to overcome these complications by coupling diagnostics with biomarkers. Further, the serum-based biomarkers have been discussed for these inborn complications and also the diagnosis with the current trend.

Effects of dietary intervention combined with insulin aspart on serum nesfatin-1 and CTRP12 levels and pregnancy outcomes in pregnant women with gestational diabetes mellitus

“…Another study found that the incidence of adverse pregnancy and perinatal outcomes in patients with GDM is greatly reduced by dietary interventions and insulin aspart treatment. [ 33 ] The results of this study showed that, after treatment, the proportion of adverse pregnancy outcomes in the observation group was significantly lower than that in the control group, and the proportions of premature infants, macrosomia, fetal distress, neonatal asphyxia, and neonatal hypoglycemia in the observation group were significantly lower than those in the control group. These results are consistent with those of the aforementioned study, which indirectly confirmed that dietary intervention combined with insulin aspart therapy can reduce adverse pregnancy and perinatal outcomes.…”

Exploring the Potential of Nanotechnology in Pediatric Healthcare: Advances, Challenges, and Future Directions

“…Nanotechnology has also improved bioavailability and reduced side effects in the treatment of neurodegenerative diseases such as Parkinson’s, Alzheimer’s, multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s, and Wilson’s diseases [ 57 ]. Additionally, nanotechnology-based approaches and biosensors hold promise for the high-performance diagnosis of gestational diabetes and jaundice, providing important monitoring tools during pregnancy [ 58 ].…”

“…In the field of pediatric medicine, nanotechnology offers innovative solutions for the diagnosis and treatment of various conditions. It has shown promise in epilepsy, expanded newborn screening, cardiovascular diseases, neuroinflammation, neurodegenerative diseases, gestational diabetes, bone disorders, mosquito-borne diseases, micronutrient deficiency, vulvovaginitis, and more [ 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 ]. Nanotechnology holds potential for tissue engineering, personalized nanomedicine, scoliosis, respiratory tract disorders, neurosensory diseases, and infections [ 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 ].…”